YESSENIA CALLENDER: Open Payments
NPI 1710316518 · EL PASO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$802 in 48 payments from 10 companies in 2025. Trend: 2023 $771 · 2024 $663 · 2025 $802
Food & beverage: $703Education: $99
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation | 20 | $187 |
| GENZYME CORPORATION | 8 | $140 |
| Janssen Biotech, Inc. | 3 | $139 |
| Lilly USA, LLC | 9 | $130 |
| Regeneron Healthcare Solutions, Inc. | 1 | $86 |
| Galderma Laboratories, L.P. | 2 | $37 |
| ABBVIE INC. | 2 | $35 |
| Journey Medical Corporation | 1 | $17 |
| Amgen Inc. | 1 | $16 |
| UCB, Inc. | 1 | $14 |
Products named: DUPIXENT, OPZELURA, TREMFYA, TALTZ, NEMLUVIO, SKYRIZI, EBGLYSS, OTEZLA.
Industry payments across TX — which companies pay providers there.
